Literature DB >> 8671682

Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR.

Q J Zhang1, Y Lindquist, V Levitsky, M G Masucci.   

Abstract

Peptides can affect the recognition of MHC class I molecules by allospecific antibodies. Two explanations have been proposed for this phenomenon. The 'conformational change' hypothesis suggests that peptide binding affects the availability of serologic determinants in the class I alpha1 and alpha2 domains while the 'peptide-side-chain effect' predicts that solvent exposed residues in the peptide are part of the serologic epitope. We have tested these possibilities by examining the recognition of peptide loaded HLA A*1101 molecules expressed in transporters associated with antigen processing (TAP)-deficient cell lines by three A11-specific mAb, and by comparing the effect of peptide analogues on the recognition of A11 complexes containing peptide epitopes from the Epstein-Barr virus nuclear antigen EBNA4 by antibodies and cytotoxic T lymphocytes (CT). The AUF5.13 and HB164 antibodies showed selective recognition of A11 molecules bound to partially overlapping sets of peptides from viral or cellular origin. The peptide dependence of AUF5.13 was confirmed in reconstitution experiments where A11 molecules were refolded at the surface of TAP-deficient T2/A11 cells that had been cultured at 26 degrees C and treated at pH3. Molecular modelling and Ala scanning mutagenesis of the IVTDFSVIK (IVT) and AVFDRKSDAK (AVF) peptides demonstrated that solvent-exposed peptide side chains affect CTL recognition as well as antibody binding. Substitution of Phe-P5 or Ser-P6 of the IVT peptide with Arg or Lys inhibited AUF5.13 recognition while binding was induced by substitution of the Arg-P5 and Lys-P6 of the AVF peptide with Ala. The results suggest that some allospecific antibodies recognized the surface of MHC class I-peptide complexes in a fashion similar to the TCR. This may involve direct interaction with the peptide side chains as well as recognition of peptide-induced perturbations in the class I complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671682     DOI: 10.1093/intimm/8.6.927

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

1.  The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

Authors:  F Micheletti; M Bazzaro; A Canella; M Marastoni; S Traniello; R Gavioli
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation.

Authors:  Judith Racape; Francine Connan; Johan Hoebeke; Jeannine Choppin; Jean-Gérard Guillet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus.

Authors:  P O Campos-Lima; V Levitsky; M P Imreh; R Gavioli; M G Masucci
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

4.  Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy.

Authors:  Chengjie Xiong; Lihong Huang; Hedan Kou; Chenwei Wang; Xiaomin Zeng; Hanli Sun; Shangyuan Liu; Bin Wu; Jingyao Li; Xiaoling Wang; Zibing Wang; Lin Chen
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

5.  Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

Authors:  Suzanne E Brooks; Stephanie A Bonney; Cindy Lee; Amy Publicover; Ghazala Khan; Evelien L Smits; Dagmar Sigurdardottir; Matthew Arno; Demin Li; Ken I Mills; Karen Pulford; Alison H Banham; Viggo van Tendeloo; Ghulam J Mufti; Hans-Georg Rammensee; Tim J Elliott; Kim H Orchard; Barbara-ann Guinn
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.